Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of rhEGF Eye Drops in Healthy Male Subjects
NCT05219461Phase 1Completed
- Sponsor
- Daewoong Bio
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nepidermin in dry eye syndrome (DED) (6 arms), sponsored by Daewoong Bio. Primary endpoint: Incidence of treatment emergent adverse events at 14 days. Started Mar 2019; status: completed.
02
Drugs
nepidermin
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT05219461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219461.